AstraZeneca Introduces At-Home FluMist Nasal Spray Vaccine
AstraZeneca has launched FluMist Home, an at-home delivery service for its nasal spray flu vaccine, approved for self- or caregiver-administration for eligible individuals aged 2-49, aiming to increase vaccination rates and provide a convenient, needle-free option. The vaccine still requires a prescription and is covered by most insurance plans, with shipping costs under $10. It is not suitable for certain populations, including children under 2, pregnant women, and those with specific health conditions.